GHI is proud to announce the launch of the Cancer Tracking System (CATSystem) Study, a pivotal initiative aimed at enhancing cervical cancer care in Kenya. This web-based intervention is designed to improve the continuum of care by facilitating timely screening, treatment, referral, and follow-up for women at risk of cervical cancer.

The study is a matched, cluster randomized controlled trial across Kenyan government hospitals, some implementing the CATSystem and some following standard care. The primary goal is to increase the number of women with positive screening results who receive timely treatment, either onsite or by referral. It also aims to improve screening uptake and minimize treatment delays.

Developed with a human-centered design approach, the CATSystem uses Kenya’s wireless infrastructure to overcome barriers in cervical cancer care. By integrating patient data from health facilities, labs, and mobile phones, the system streamlines communication among providers and improves patient retention during treatment.

Early feedback from providers and patients has been positive, showing strong acceptability and feasibility. The study also includes a cost-effectiveness evaluation to guide decisions on scaling the system in low-resource settings.

This initiative underscores GHI’s commitment to leveraging innovative digital solutions to improve health outcomes. By addressing critical gaps in cervical cancer care, the CATSystem Study has the potential to make a significant impact on women’s health in Kenya and beyond.